English | 简体中文 | 繁體中文 | 한국어
Share:
Bavarian Nordic to Host First Quarter 2018 Results Conference Call

COPENHAGEN, Denmark - May 16, 2018 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Lubrizol Holds Ribbon Cutting Ceremony to Celebrate TPU Expansion in Avon Lake  
May 25, 2018 21:43 ET
NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020  
May 25, 2018 19:00 ET
Intervest Offices & Warehouses takes the next step in the Genk Green Logistics project  
May 25, 2018 17:40 ET
Corbion General Shareholders Meeting approves Board reappointments and dividend  
May 25, 2018 17:29 ET
Hexagon Composites ASA: Mandatory notification of trade  
May 25, 2018 17:16 ET
Klövern AB (publ): Klövern publishes prospectus and applies for listing of bond loan on Nasdaq Stockholm  
May 25, 2018 16:00 ET
Lubrizol Appoints Apta as New Distributor in Brazil  
May 24, 2018 19:03 ET
Argus Launches New Industry-Leading Regulatory and Compliance Solution on Cloud  
May 22, 2018 08:03 ET
INGREDION INCORPORATED DECLARES QUARTERLY DIVIDEND OF $0.60 PER SHARE  
May 16, 2018 23:33 ET
Sequa Petroleum N.V. Bonds Update  
May 15, 2018 15:43 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: